• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    3/13/24 9:06:03 AM ET
    $AGRX
    $ATNF
    $CELU
    $CMPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRX alert in real time by email

    Gainers

    • NuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 25.0% to $0.1. The market value of their outstanding shares is at $4.0 million.
    • Agile Therapeutics (NASDAQ:AGRX) stock moved upwards by 19.34% to $0.87. The company's market cap stands at $2.5 million.
    • Compass Therapeutics (NASDAQ:CMPX) stock moved upwards by 14.97% to $2.38. The company's market cap stands at $303.4 million.
    • HUTCHMED (China) (NASDAQ:HCM) stock increased by 14.04% to $18.62. The company's market cap stands at $3.1 billion.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 13.14% to $0.62. The market value of their outstanding shares is at $22.2 million.

    Losers

    • P3 Health Partners (NASDAQ:PIII) shares decreased by 14.7% to $0.87 during Wednesday's pre-market session. The market value of their outstanding shares is at $100.2 million.
    • 180 Life Sciences (NASDAQ:ATNF) shares fell 12.69% to $3.51. The market value of their outstanding shares is at $2.5 million.
    • CryoPort (NASDAQ:CYRX) shares decreased by 10.39% to $14.61. The market value of their outstanding shares is at $715.2 million. As per the news, the Q4 earnings report came out yesterday.
    • Renalytix (NASDAQ:RNLX) stock fell 9.9% to $0.82. The company's market cap stands at $40.9 million.
    • Celularity (NASDAQ:CELU) shares declined by 8.57% to $5.39. The market value of their outstanding shares is at $117.4 million.
    • Inspire Veterinary (NASDAQ:IVP) shares fell 8.21% to $0.04. The company's market cap stands at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $ATNF
    $CELU
    $CMPX

    CompanyDatePrice TargetRatingAnalyst
    Compass Therapeutics Inc.
    $CMPX
    2/13/2026$15.00Buy
    Craig Hallum
    Compass Therapeutics Inc.
    $CMPX
    1/5/2026Outperform
    William Blair
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Buy
    Canaccord Genuity
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025Overweight
    Cantor Fitzgerald
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    CryoPort Inc.
    $CYRX
    8/6/2025Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chiu Lorenso

    3 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    3/18/26 5:52:27 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kay Andrew Martin

    3 - NuCana plc (0001709626) (Issuer)

    3/18/26 5:36:55 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Webster Ian Alexander

    3 - NuCana plc (0001709626) (Issuer)

    3/18/26 5:39:28 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ATNF
    $CELU
    $CMPX
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by NuCana plc

    SCHEDULE 13D - NuCana plc (0001709626) (Subject)

    3/18/26 6:39:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    3/16/26 6:09:54 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by CryoPort Inc.

    144 - Cryoport, Inc. (0001124524) (Subject)

    3/12/26 4:17:33 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Compass Therapeutics with a new price target

    Craig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00

    2/13/26 8:35:30 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on Compass Therapeutics

    William Blair initiated coverage of Compass Therapeutics with a rating of Outperform

    1/5/26 8:57:39 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Compass Therapeutics with a new price target

    Citizens JMP initiated coverage of Compass Therapeutics with a rating of Mkt Outperform and set a new price target of $10.00

    12/3/25 8:37:10 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:30:55 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:25:57 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for fourth quarter and full year 2025 on Thursday, March 26, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter and Full Year 2025 Earnings Conference Call Date & Time March 26, 2026, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 International 1-412-317-0692 Ask to be joined into t

    3/13/26 8:05:00 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its

    3/12/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

    Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026

    3/12/26 8:30:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by P3 Health Partners Inc.

    SC 13G - P3 Health Partners Inc. (0001832511) (Subject)

    11/14/24 4:33:46 PM ET
    $PIII
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by CryoPort Inc.

    SC 13G - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 4:02:52 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ATNF
    $CELU
    $CMPX
    Financials

    Live finance-specific insights

    View All

    P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for fourth quarter and full year 2025 on Thursday, March 26, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter and Full Year 2025 Earnings Conference Call Date & Time March 26, 2026, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 International 1-412-317-0692 Ask to be joined into t

    3/13/26 8:05:00 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care